{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T09:10:31Z","timestamp":1759569031713,"version":"build-2065373602"},"reference-count":37,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":2807,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.exphem.2014.06.003","type":"journal-article","created":{"date-parts":[[2014,6,23]],"date-time":"2014-06-23T11:15:18Z","timestamp":1403522118000},"page":"867-874.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Distinct in\u00a0vitro sensitivity of p53-mutated and ATM-mutated chronic lymphocytic leukemia cells to ofatumumab and rituximab"],"prefix":"10.1016","volume":"42","author":[{"given":"Ludmila","family":"Sebejova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marek","family":"Borsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuzana","family":"Jaskova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Potesil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronika","family":"Navrkalova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jitka","family":"Malcikova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Sramek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Doubek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomas","family":"Loja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarka","family":"Pospisilova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiri","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Trbusek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2014.06.003_bib1","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"D\u00f6hner","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2014.06.003_bib2","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1182\/blood-2009-05-224071","article-title":"Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial","volume":"114","author":"Zenz","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2014.06.003_bib3","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1182\/blood.V98.3.814","article-title":"p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation","volume":"98","author":"Pettitt","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2014.06.003_bib4","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1200\/JCO.2010.32.0838","article-title":"Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial","volume":"29","author":"Gonzalez","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2014.06.003_bib5","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1200\/JCO.2005.03.1021","article-title":"Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy","volume":"24","author":"Byrd","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2014.06.003_bib6","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1182\/blood-2010-08-304683","article-title":"Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL","volume":"117","author":"Badoux","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2014.06.003_bib7","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood.V89.7.2516","article-title":"11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis","volume":"89","author":"D\u00f6hner","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2014.06.003_bib8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3324\/haematol.2011.049270","article-title":"ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression","volume":"97","author":"Guarini","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2014.06.003_bib9","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.exphem.2014.06.003_bib10","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/cncr.23993","article-title":"Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia","volume":"115","author":"Tsimberidou","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.exphem.2014.06.003_bib11","doi-asserted-by":"crossref","first-page":"5448","DOI":"10.1200\/JCO.2007.11.2649","article-title":"Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion","volume":"25","author":"Austen","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2014.06.003_bib12","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3324\/haematol.2012.081620","article-title":"ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin","volume":"98","author":"Navrkalova","year":"2013","journal-title":"Haematologica"},{"issue":"352 Pt","key":"10.1016\/j.exphem.2014.06.003_bib13","first-page":"1","article-title":"Strategies for manipulating the p53 pathway in the treatment of human cancer","volume":"1","author":"Hupp","year":"2000","journal-title":"Biochem J"},{"key":"10.1016\/j.exphem.2014.06.003_bib14","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1517\/14712598.2012.735655","article-title":"Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia","volume":"13","author":"Jain","year":"2013","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.exphem.2014.06.003_bib15","first-page":"676","article-title":"Mechanisms of action of CD20 antibodies","volume":"2","author":"Boross","year":"2012","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.exphem.2014.06.003_bib16","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in\u00a0vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2014.06.003_bib17","doi-asserted-by":"crossref","first-page":"362","DOI":"10.4049\/jimmunol.177.1.362","article-title":"The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20","volume":"177","author":"Teeling","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.exphem.2014.06.003_bib18","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1182\/blood-2004-01-0039","article-title":"Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas","volume":"104","author":"Teeling","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2014.06.003_bib19","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1200\/JCO.2009.25.3187","article-title":"Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia","volume":"28","author":"Wierda","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2014.06.003_bib20","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.1002\/cncr.28292","article-title":"Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL)","volume":"119","author":"Shanafelt","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.exphem.2014.06.003_bib21","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1182\/blood-2009-07-234708","article-title":"Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage","volume":"114","author":"Malcikova","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2014.06.003_bib22","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4049\/jimmunol.1202645","article-title":"Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy","volume":"190","author":"Bologna","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.exphem.2014.06.003_bib23","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1365-2141.2010.08428.x","article-title":"Comparison of the in\u00a0vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells","volume":"152","author":"Patz","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2014.06.003_bib24","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1182\/blood.V98.12.3383","article-title":"CD20 levels determine the in\u00a0vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59","volume":"98","author":"Golay","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2014.06.003_bib25","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.4049\/jimmunol.1302954","article-title":"Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity In: Chronic Lymphocytic Leukemia","volume":"192","author":"Baig","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.exphem.2014.06.003_bib26","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.4049\/jimmunol.172.5.3280","article-title":"Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia","volume":"172","author":"Kennedy","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.exphem.2014.06.003_bib27","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/j.leukres.2008.05.014","article-title":"Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab","volume":"32","author":"Zent","year":"2008","journal-title":"Leuk Res"},{"key":"10.1016\/j.exphem.2014.06.003_bib28","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.blre.2011.02.002","article-title":"Importance of genetics in chronic lymphocytic leukemia","volume":"25","author":"Zenz","year":"2011","journal-title":"Blood Rev"},{"key":"10.1016\/j.exphem.2014.06.003_bib29","first-page":"4237","article-title":"The complement\u00a0inhibitor CD59 and the lymphocyte function-associated antigen-3\u00a0(LFA-3, CD58) genes possess functional binding sites for the p53 tumor suppressor protein","volume":"22","author":"Gazouli","year":"2002","journal-title":"Anticancer Res"},{"key":"10.1016\/j.exphem.2014.06.003_bib30","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1054\/mehy.2001.1476","article-title":"P53 possibly upregulates the expression of CD58 (LFA-3) and CD59 (MIRL)","volume":"58","author":"Sampaziotis","year":"2002","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.exphem.2014.06.003_bib31","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/nature03482","article-title":"DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis","volume":"434","author":"Bartkova","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2014.06.003_bib32","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0167-5699(94)90276-3","article-title":"CD20: a regulator of cell-cycle progression of B lymphocytes","volume":"15","author":"Tedder","year":"1994","journal-title":"Immunol Today"},{"key":"10.1016\/j.exphem.2014.06.003_bib33","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.freeradbiomed.2007.10.048","article-title":"Regulation of CD20 expression by radiation-induced changes in intracellular redox status","volume":"44","author":"Gupta","year":"2008","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.exphem.2014.06.003_bib34","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/sj.onc.1204111","article-title":"Ataxia-telangiectasia: chronic activation of damage-responsive functions is reduced by alpha-lipoic acid","volume":"20","author":"Gatei","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2014.06.003_bib35","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1038\/sj.onc.1205557","article-title":"Ubiquitination capabilities in response to neocarzinostatin and H(2)O(2) stress in cell lines from patients with ataxia-telangiectasia","volume":"21","author":"Taylor","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2014.06.003_bib36","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1038\/nm1320","article-title":"The antioxidant function of the p53 tumor suppressor","volume":"11","author":"Sablina","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.exphem.2014.06.003_bib37","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2141.2008.07012.x","article-title":"Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients","volume":"141","author":"Tam","year":"2008","journal-title":"Br J Haematol"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X14002379?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X14002379?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:32:15Z","timestamp":1759566735000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X14002379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0301472X14002379"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2014.06.003","relation":{},"ISSN":["0301-472X"],"issn-type":[{"type":"print","value":"0301-472X"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Distinct in\u00a0vitro sensitivity of p53-mutated and ATM-mutated chronic lymphocytic leukemia cells to ofatumumab and rituximab","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2014.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 ISEH - International Society for Experimental Hematology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}